HomeORMP • NASDAQ
Oramed Pharmaceuticals, Inc.
$2.20
Pre-market:
$2.26
(2.73%)+0.060
Closed: Apr 19, 4:38:57 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$2.33
Day range
$2.14 - $2.37
Year range
$1.67 - $5.25
Market cap
89.14M USD
Avg Volume
132.58K
P/E ratio
16.15
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
0.00-100.00%
Operating expense
3.88M-62.80%
Net income
13.34M256.10%
Net profit margin
Earnings per share
0.33250.00%
EBITDA
-3.82M60.67%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
162.05M4.06%
Total assets
220.55M36.44%
Total liabilities
57.66M449.86%
Total equity
162.89M
Shares outstanding
40.52M
Price to book
0.57
Return on assets
-4.29%
Return on capital
-4.42%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
13.34M256.10%
Cash from operations
-1.42M82.41%
Cash from investing
30.00M166.40%
Cash from financing
-25.00M-698.80%
Net change in cash
3.59M-50.65%
Free cash flow
-3.14M41.52%
About
Oramed Pharmaceuticals, or Oramed, is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. Wikipedia
Founded
2006
Website
Employees
15
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu